Lineage Cell Therapeutics Short Interest Ratio and Short Volume

Short interest is the volume of Lineage Cell Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 5,430,000 shares of LCTX short.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. Lineage Cell Therapeutics currently has a short interest ratio of 4.0.

Lineage Cell Therapeutics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 5,430,000 shares, an increase of 1.9% from the previous total of 5,330,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.00% of Lineage Cell Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Lineage Cell Therapeutics: C4 Therapeutics, Inc. (9.00%), Krystal Biotech, Inc. (7.52%), REGENXBIO Inc. (10.09%), Alector, Inc. (10.91%), Curis, Inc. (0.00%), Forma Therapeutics Holdings, Inc. (9.85%), Translate Bio, Inc. (0.00%), Atara Biotherapeutics, Inc. (0.00%), Cortexyme, Inc. (26.33%), and Coherus BioSciences, Inc. (19.69%).

As of the most recent reporting period, the following stocks had the largest short interest positions: Analog Devices, Inc. ($5.85 billion), Aon plc ($5.61 billion), Charter Communications, Inc. ($5.44 billion), Snap Inc. ($3.49 billion), Airbnb, Inc. ($3.35 billion), Peloton Interactive, Inc. ($2.53 billion), ViacomCBS Inc. ($2.48 billion), Expedia Group, Inc. ($2.39 billion), The Kroger Co. ($2.26 billion), and Nuance Communications, Inc. ($2.18 billion). View all of the most shorted stocks.

Short selling LCTX is an investing strategy that aims to generate trading profit from Lineage Cell Therapeutics as its price is falling. Lineage Cell Therapeutics' stock is trading up $0.07 today. To short Lineage Cell Therapeutics stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Lineage Cell Therapeutics will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Lineage Cell Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of LCTX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LCTX, twice per month. The most recent reporting period available is April, 15 2021.